News Denali Therapeutics Inc.

Equities

DNLI

US24823R1059

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-23 pm EDT			5-day change	1st Jan Change
16.11 ^USD	+0.75%		-7.09%	-24.93%

Apr. 09	UBS Adjusts Denali Therapeutics Price Target to $32 From $70, Maintains Buy Rating	MT
Apr. 03	Denali Therapeutics Insider Sold Shares Worth $1,896,250, According to a Recent SEC Filing	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences	Apr. 09	AQ
UBS Adjusts Denali Therapeutics Price Target to $32 From $70, Maintains Buy Rating	Apr. 09	MT
Denali Therapeutics Insider Sold Shares Worth $1,896,250, According to a Recent SEC Filing	Apr. 03	MT
Denali Therapeutics Files Prospectus for Secondary Offering	Mar. 22	MT
Denali Therapeutics Inc. announced that it has received $499.73271 million in funding from Baker Bros. Advisors LP and other investors	Feb. 29	CI
B. Riley Securities Adjusts Denali Therapeutics' Price Target to $36 From $38, Keeps Buy Rating	Feb. 28	MT
Denali Shares Rise on PIPE Deal, Plan to Spin Out Preclinical Small Molecule Portfolio	Feb. 27	MT
Denali Q4 Net Loss Widens; Launching PIPE Deal, Plans to Spin Out Preclinical Small Molecule Portfolio; Shares Jump Pre-Bell	Feb. 27	MT
Denali Therapeutics Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 27	CI
Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights	Feb. 27	GL
Denali Therapeutics Announces $500 million Private Placement Equity Financing	Feb. 27	GL
Denali Therapeutics Announces $500 million Private Placement Equity Financing	Feb. 27	AQ
Denali Therapeutics Inc. announced that it expects to receive $499.73271 million in funding from Baker Bros. Advisors LP and other investors	Feb. 26	CI
North American Morning Briefing : S&P 500 Futures -2-	Feb. 23	DJ
Sanofi Informs Denali That Potential ALS Drug Misses Primary Endpoint of Phase 2 Study	Feb. 20	MT
Denali Therapeutics Shares Fall After ALS Treatment Misses Primary Endpoint	Feb. 16	DJ
Sanofi: failure of a phase 2 trial against ALS	Feb. 16	CF
Denali Therapeutics Insider Sold Shares Worth $402,420, According to a Recent SEC Filing	Feb. 16	MT
Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™	Feb. 07	GL
Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™	Feb. 07	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Denali Therapeutics Inc.

Equities

DNLI

US24823R1059

Summary

Filters